THE EXPERIENCE OF THE USAGE OF BLOCKER OF AT1-ANGIOTENZINE RECEPTOR APROVEL ON HYPERTENSIVE PATIENTS

  • G.V. Dzyak
  • T.V. Kolesnik
Keywords: hypertension, AT1-angiotenzine receptor blocker, aprovel, blood pressure monitoring

Abstract

The aim of  the research was to study clinical effects and acceptability of a new AT1-recepotor blocker – irbesartan (aprovel, Sanofi/BMS). 30 patients with soft and moderate arterial hypertension were examined, the average age of the examined persons is 52,6±6,1 years old, duration of disease - 9,7 years. The prescribed dose of aprovel was 150 mg per day for 12 weeks, the dose was corrected after 4 weeks of therapy. All the patients passed 24 hours’ blood pressure monitoring ( device of MEDITEX, ABPM, Hungary) before the start of treatment and on 4, 8, 12after it. The following indices were analyzed: middle systolic and diastolic blood pressure (24-hours, day, night), variability of blood pressure, hypertension time and square indices.  

This study showed the efficacy of aprovel monotherapy (the dose made up 150 – 300 mg per day). The preparation causes a stable hypotensive effect, decreasing systolic and diastolic blood pressure after 6 – 8 week of treatment. The hypotensive effect of aprovel depends on the dose of the preparation. Aprovel does not influence normal circadian low daily blood pressure rhythm and corrects pathologicone. 

Downloads

Download data is not yet available.

References

1. Alderman M.N., Ooi W.L., Madhavan S., et al. Plazma renin aktivity: a risk factor for myocardial infection in hypertensive patients. // Amer J Hypertens. 1997. V. 10. P. 1-8.

2. Meredith P. Organ protection and optimal blood pressure control. // Amer J Hypertens. 1995. V.8:2. P.59-62.

3. Griendling K.K., Murphy Т.О., Alexander R.W. Molecular biologi of renin-angiotensin system. // Circulation 1993. V. 8. P. 1816-1826.

4. Urata II., Boehm K.D., Philip A. Et al. Ctllular localization and regional distribution of an angiotensin IT - forming chimase in the heaart. // J Clin Invest. 1993. V. 91. P. 11269-1281.
How to Cite
Dzyak, G., & Kolesnik, T. (1). THE EXPERIENCE OF THE USAGE OF BLOCKER OF AT1-ANGIOTENZINE RECEPTOR APROVEL ON HYPERTENSIVE PATIENTS. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (2), 29-34. Retrieved from https://periodicals.karazin.ua/medicine/article/view/7429
Issue
No. 2 (2001)
Section
Clinical research

The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.